Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xilio Therapeutics (XLO) Enterprise Value (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Enterprise Value for 2 consecutive years, with -$137.5 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value fell 148.68% to -$137.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$137.5 million through Dec 2025, down 148.68% year-over-year, with the annual reading at -$137.5 million for FY2025, 148.68% down from the prior year.
  • Enterprise Value hit -$137.5 million in Q4 2025 for Xilio Therapeutics, down from -$103.8 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$34.0 million in Q1 2024 to a low of -$137.5 million in Q4 2025.